Who is tmunity Therapeutics?
ABOUT TMUNITY THERAPEUTICS Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.
Why is Yumanity Therapeutics (ymtx) stock up 50% today?
Why Is Yumanity Therapeutics (YMTX) Stock Up 50% Today? Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform.
What is Yumanity Therapeutics?
Yumanity Therapeutics, Inc. is a clinical stage biopharmaceuticals company. It is accelerating the revolution in the treatment of neurodegenerative diseases through its transformative scientific foundation and drug discovery platform.
What is tmunity?
“Extraordinary advances have already been made with the development of the first generation of cell-based immunotherapies for cancer. We formed Tmunity, bringing together all the essential expertise, technology and scientific insight, to make the next great leap, to deliver the full promise of T cell medicine to patients.”
Tmunity Comparisons
Tmunity Signals
Developer of a biotherapeutics platform designed to deliver cell immunotherapy to patients with devastating diseases. Th
Where is the Tmunity clinic located?
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
What is T cell immunotherapy?
With headquarters in Philadelphia, Tmunity ...
What is YTX-7739?
Tmunity Therapeutics is a private biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to more patients with devastating diseases.
What is YMTX 2021?
YTX-7739 inhibits the enzyme SCD, which catalyzes the conversion of two saturated fatty acids to unsaturated fatty acids. Increased concentrations of unsaturated fatty acids alter cell membrane structure, resulting in alpha-synuclein aggregation, neuronal toxicity, and neurodegeneration.
Is YTX 7739 safe?
BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT. A live audio webcast of the presentation can be accessed through the Events section of the Company's website at yumanity.com/events. An archived replay of the webcast will be available on the Company's website following the live presentation. About Yumanity TherapeuticsYumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease), frontotemporal lobar dementia (FTLD), and Alzheimer’s disease. For more information, please visit www.yumanity.com. Investors:Burns McClellan, Inc.Lee [email protected] (212) 213-0006 Media:Burns McClellan, Inc.Ryo Imai / Robert Flamm, [email protected] / [email protected] (212) 213-0006
How long does YTX-7739 last?
YTX-7739 demonstrated target engagement in Phase 1b clinical trial in patients with mild-to-moderate Parkinson’s disease YTX-7739 found to be generally well tolerated, demonstrating favorable pharmacokinetic/pharmacodynamic (PK/PD) profiles and a safety profile with no serious adverse events Conference call scheduled for 8:30 a.m. EST, Wednesday, November 10 BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX) is a clinical-stage biopharmaceutical company focused on the
Is YTX-7739 a treatment for Parkinson's disease?
The drug candidate demonstrated a half-life of 47 to 72 hours suggesting once-daily dosing. YTX-7739 was also shown to cross the blood brain barrier with a single, oral dose.
Is Yumanity a non-statutory stock?
YTX-7739 is currently in clinical development by Yumanity Therapeutics as a potential treatment for Parkinson’s disease. The research entitled, Targeting Fatty Acid Biosynthesis in Glioblastoma, was conducted in the laboratory of Christian E. Badr, Ph.D., of Massachusetts General Hospital and presented by Katharina M. Eyme.
